Marijke E B Kremer1, Joep P M Derikx1,2, Leontien C M Kremer3, Robertine van Baren4, Hugo A Heij5, Marc H W A Wijnen6, René M H Wijnen7, David C van der Zee8, L W Ernest van Heurn9,10. 1. Department of Pediatric Surgery, Maastricht University Medical Center, Maastricht, The Netherlands. 2. Paediatric Surgical Center of Amsterdam Emma Children's Hospital AMC and VU University Medical Center, P.O. Box 22660, 1100 DD, Amsterdam, The Netherlands. 3. Department of Pediatric Oncology, Emma Children's Hospital, University Medical Center Amsterdam, Amsterdam, The Netherlands. 4. Department of Pediatric Surgery, University Medical Center Groningen, Groningen, The Netherlands. 5. Pediatric Surgical Center of Amsterdam (Emma Children's Hospital University Medical Center and VU Medical Center Amsterdam), Amsterdam, The Netherlands. 6. Department of Pediatric Surgery, University Medical Center Nijmegen, Nijmegen, The Netherlands. 7. Department of Pediatric Surgery, Sophia Children's Hospital, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands. 8. Department of Pediatric Surgery, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, The Netherlands. 9. Department of Pediatric Surgery, Maastricht University Medical Center, Maastricht, The Netherlands. e.vanheurn@amc.uva.nl. 10. Paediatric Surgical Center of Amsterdam Emma Children's Hospital AMC and VU University Medical Center, P.O. Box 22660, 1100 DD, Amsterdam, The Netherlands. e.vanheurn@amc.uva.nl.
Abstract
PURPOSE: The impact of chemotherapeutic sequelae on long-term quality of life (QoL) for survivors of malignant sacrococcygeal teratoma (SCT) is unknown. The incidence of chemotherapeutic toxicity in patients treated for malignant SCT and possible effects on the QoL were analyzed. METHODS: Retrospective chart review of patients ≥18 years treated for SCT in the Netherlands was performed. Present QoL was evaluated using the SF-36 questionnaire. The results of survivors of malignant SCT were compared to those of patients treated for benign SCT. RESULTS: Fifty-one of 76 traceable patients consented to participate. The results of 47 (92.2 %), 9 men and 38 women (median age 25.4 years, range 18.3-41.2), were analyzed. Eleven had been treated for malignancy; 63.6 % suffered from at least one chemotherapeutic sequel with hearing loss as the most common one. Results for both groups were similar on all but one SF-36 subcategory; those treated for malignant tumor scored significantly lower on the subcategory physical functioning (p = 0.02). CONCLUSION: Despite the high incidence of chemotherapeutic sequelae among survivors of malignant SCT, their QoL does not differ from that of those treated for benign SCT. Even though their physical functioning is restricted, daily activities and psychosocial functioning of survivors of malignant SCT are not restricted.
PURPOSE: The impact of chemotherapeutic sequelae on long-term quality of life (QoL) for survivors of malignant sacrococcygeal teratoma (SCT) is unknown. The incidence of chemotherapeutic toxicity in patients treated for malignant SCT and possible effects on the QoL were analyzed. METHODS: Retrospective chart review of patients ≥18 years treated for SCT in the Netherlands was performed. Present QoL was evaluated using the SF-36 questionnaire. The results of survivors of malignant SCT were compared to those of patients treated for benign SCT. RESULTS: Fifty-one of 76 traceable patients consented to participate. The results of 47 (92.2 %), 9 men and 38 women (median age 25.4 years, range 18.3-41.2), were analyzed. Eleven had been treated for malignancy; 63.6 % suffered from at least one chemotherapeutic sequel with hearing loss as the most common one. Results for both groups were similar on all but one SF-36 subcategory; those treated for malignant tumor scored significantly lower on the subcategory physical functioning (p = 0.02). CONCLUSION: Despite the high incidence of chemotherapeutic sequelae among survivors of malignant SCT, their QoL does not differ from that of those treated for benign SCT. Even though their physical functioning is restricted, daily activities and psychosocial functioning of survivors of malignant SCT are not restricted.
Entities:
Keywords:
Chemotherapeutic sequelae; Malignant sacrococcygeal teratoma; Quality of life
Authors: G A Hale; N M Marina; D Jones-Wallace; C A Greenwald; J J Jenkins; B N Rao; X Luo; M M Hudson Journal: J Pediatr Hematol Oncol Date: 1999 Mar-Apr Impact factor: 1.289
Authors: N K Aaronson; M Muller; P D Cohen; M L Essink-Bot; M Fekkes; R Sanderman; M A Sprangers; A te Velde; E Verrips Journal: J Clin Epidemiol Date: 1998-11 Impact factor: 6.437
Authors: F Rescorla; D Billmire; C Stolar; C Vinocur; P Colombani; J Cullen; R Giller; B Cushing; S Lauer; M Davis; E Hawkins; J Shuster; M Krailo Journal: J Pediatr Surg Date: 2001-01 Impact factor: 2.545
Authors: U Göbel; G Calaminus; M Blohm; D Booss; F Felberbauer; U Hofmann; A M Holschneider; U Willnow; D Harms Journal: Klin Padiatr Date: 1997 Jul-Aug Impact factor: 1.349
Authors: G Calaminus; D T Schneider; J P M Bökkerink; H Gadner; D Harms; R Willers; U Göbel Journal: J Clin Oncol Date: 2003-03-01 Impact factor: 44.544
Authors: U Göbel; G Calaminus; C Teske; M Bamberg; J P Bökkerink; R J Haas; A M Holschneider; G Janka-Schaub; H Jürgens; U Mittler Journal: Klin Padiatr Date: 1993 Jul-Aug Impact factor: 1.349
Authors: K P Schropp; T E Lobe; B Rao; K Mutabagani; G A Kay; B F Gilchrist; P G Philippe; E T Boles Journal: J Pediatr Surg Date: 1992-08 Impact factor: 2.545